SLGC - SomaLogic, Inc. Stock Price, Fair Value and News

2.10USD Market Closed

Market Summary

USD2.10

Market Closed

SLGC Stock Price

View Fullscreen

SLGC RSI Chart

SLGC Valuation

Market Cap

395.0M

Price/Earnings (Trailing)

-3.03

Price/Sales (Trailing)

4.83

EV/EBITDA

-0.73

Price/Free Cashflow

-3.26

SLGC Price/Sales (Trailing)

SLGC Profitability

EBT Margin

-159.08%

Return on Equity

-26.25%

Return on Assets

-23.07%

Free Cashflow Yield

-30.69%

SLGC Fundamentals

SLGC Revenue

Revenue (TTM)

81.7M

SLGC Earnings

Earnings (TTM)

-130.4M

Breaking Down SLGC Revenue

Last 7 days

-17%

Last 30 days

-25.8%

Last 90 days

-0.9%

Trailing 12 Months

-16.3%

How does SLGC drawdown profile look like?

SLGC Financial Health

Current Ratio

17.79

SLGC Investor Care

Shares Dilution (1Y)

0.29%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	95.1M	101.4M	81.7M	0
2022	85.7M	80.1M	101.8M	97.7M
2021	62.3M	68.8M	75.2M	81.6M
2020	0	0	0	55.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About SomaLogic, Inc.

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

CEO	Mr. Adam Taich
WEBSITE	somalogic.com
INDUSTRY	Healthcare Plans
EMPLOYEES	451

SomaLogic, Inc. Frequently Asked Questions

What is the ticker symbol for SomaLogic, Inc.? What does SLGC stand for in stocks?

SLGC is the stock ticker symbol of SomaLogic, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SomaLogic, Inc. (SLGC)?

As of Fri Jan 05 2024, market cap of SomaLogic, Inc. is 394.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLGC stock?

You can check SLGC's fair value in chart for subscribers.

Is SomaLogic, Inc. a good stock to buy?

The fair value guage provides a quick view whether SLGC is over valued or under valued. Whether SomaLogic, Inc. is cheap or expensive depends on the assumptions which impact SomaLogic, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLGC.

What is SomaLogic, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 05 2024, SLGC's PE ratio (Price to Earnings) is -3.03 and Price to Sales (PS) ratio is 4.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLGC PE ratio will change depending on the future growth rate expectations of investors.